Search This Blog

Friday, February 1, 2013

McKesson Reports Fiscal 2013 Third-Quarter Results January 31, 2013

McKesson News Release:

McKesson Reports Fiscal 2013 Third-Quarter Results
January 31, 2013

McKesson Corporation (NYSE: MCK) today reported that revenues for the third quarter ended December 31, 2012 were $31.2 billion, up 1% compared to $30.8 billion a year ago.

  • Revenues of $31.2 billion for the third quarter, up 1%.
  • Third-quarter GAAP earnings per diluted share of $1.24, up 3%.
  • Third-quarter Adjusted Earnings per diluted share of $1.41, up 1%.
  • Board of Directors authorized an additional $500 million share repurchase program.
  • Fiscal 2013 Outlook:  Adjusted Earnings per diluted share of $7.10 to $7.30.
SAN FRANCISCO, January 31, 2013 – McKesson Corporation (NYSE: MCK) today reported that revenues for the third quarter ended December 31, 2012 were $31.2 billion, up 1% compared to $30.8 billion a year ago.  On the basis of U.S. generally accepted accounting principles (“GAAP”), third-quarter earnings per diluted share was $1.24 compared to $1.20 a year ago.  
Third-quarter Adjusted Earnings per diluted share was $1.41, up 1% compared to $1.40 a year ago.  
For the first nine months of the fiscal year, McKesson generated cash from operations of $276 million, and ended the quarter with cash and cash equivalents of $2.7 billion.  During the first nine months of the fiscal year, the company paid $147 million in dividends, had internal capital spending of $268 million and spent $577 million on acquisitions.   The company also repurchased $360 million of its common stock during the third quarter.  
Distribution Solutions revenues were up 1% in the third quarter, driven mainly by growth in our U.S. pharmaceutical direct distribution and services business and growth in our Medical-Surgical distribution business.    
Canadian revenues, on a constant currency basis, increased 3% for the third quarter.  Including the favorable currency impact of 3%, Canadian revenues increased 6% for the third quarter.  
Medical-Surgical distribution and services revenues were up 15% for the third quarter, driven by market growth, new customers, acquisitions and one additional sales day.
In the third quarter, Distribution Solutions GAAP operating profit was $525 million and GAAP operating margin was 1.73%.  Third-quarter adjusted operating profit was $569 million and the adjusted operating margin was 1.87%.  Distribution Solutions third-quarter segment results include a $40 million pre-tax charge related to a legal dispute in our Canadian business.
Technology Solutions revenues were flat in the third quarter compared to the prior year.  GAAP operating profit was $79 million for the third quarter and GAAP operating margin was 9.56%.  Adjusted operating profit was $98 million for the third quarter and adjusted operating margin was 11.86%.  Technology Solutions third-quarter segment results were impacted by revenue deferral in our international business.
“Our full year view of the operating performance in our Distribution Solutions segment is now better than our original expectations, and our full year view of the operating performance in the primary businesses in Technology Solution remains unchanged,” said John H. Hammergren, chairman and chief executive officer.   “This operating strength is offset by the charge in our Canadian business and revenue deferral in our international technology business, and as a result we are updating our previous outlook for the fiscal year and now expect Adjusted Earnings per diluted share of $7.10 to $7.30 for the fiscal year ending March 31, 2013.”
Fiscal Year 2013 Outlook
McKesson expects Adjusted Earnings per diluted share of $7.10 to $7.30 for the fiscal year ending March 31, 2013, which excludes the following GAAP items:
  • Amortization of acquisition-related intangible assets of approximately 55 cents per diluted share in Fiscal 2013. 
  • Acquisition expenses and related adjustments expected to add approximately 13 cents per diluted share, including the impact of the $81 million pre-tax gain on business combination related to the acquisition of the remaining 50% ownership in McKesson’s corporate headquarters building completed during the first quarter.
  • Litigation reserve adjustments of approximately 15 cents per diluted share.
Adjusted Earnings
McKesson separately reports financial results on the basis of Adjusted Earnings.  Adjusted Earnings is a non-GAAP financial measure defined as GAAP income from continuing operations, excluding amortization of acquisition-related intangible assets, acquisition expenses and related adjustments, and certain litigation reserve adjustments.  A reconciliation of McKesson’s financial results determined in accordance with GAAP to Adjusted Earnings is provided in Schedules 2, 3 and 4 of the financial statement tables included with this release. 
Risk Factors
Except for historical information contained in this press release, matters discussed may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.  These statements may be identified by their use of forward-looking terminology such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates” or the negative of these words or other comparable terminology.  The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements.  It is not possible to predict or identify all such risks and uncertainties; however, the most significant of these risks and uncertainties are described in the company’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission and include, but are not limited to: material adverse resolution of pending legal proceedings; changes in the U.S. healthcare industry and regulatory environment; changes in the Canadian healthcare industry and regulatory environment; competition; substantial defaults in payment or a material reduction in purchases by, or the loss of, a large customer or group purchasing organization; the loss of government contracts as a result of compliance or funding challenges; public health issues in the U.S. or abroad; implementation delay, malfunction, failure or breach of internal information systems; the adequacy of insurance to cover property loss or liability claims; the company’s failure to attract and retain customers for its software products and solutions due to integration and implementation challenges, or due to an inability to keep pace with technological advances; the company’s proprietary products and services may not be adequately protected, and its products and solutions may be found to infringe on the rights of others; system errors or failure of our technology products and solutions to conform to specifications; disaster or other event causing interruption of customer access to data residing in our service centers; the delay or extension of our sales or implementation cycles for external software products; changes in circumstances that could impair our goodwill or intangible assets; foreign currency fluctuations or disruptions to our foreign operations; new or revised tax legislation or challenges to our tax positions; the company’s ability to successfully identify, consummate and integrate strategic acquisitions; general economic conditions, including changes in the financial markets that may affect the availability and cost of credit to the company, its customers or suppliers; and changes in accounting principles generally accepted in the United States of America.  The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made.  Except to the extent required by law, the company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.
The company has scheduled a conference call for 5:00 PM ET.  The dial-in number for individuals wishing to participate on the call is 719-234-7317.  Erin Lampert, vice president, Investor Relations, is the leader of the call, and the password to join the call is ‘McKesson’.  A replay of this conference call will be available for five calendar days.   The dial-in number for individuals wishing to listen to the replay is 888-203-1112 and the pass code is 8164902.  A webcast of the conference call will also be available live and archived on the company’s Investor Relations website atwww.mckesson.com/investors. 
Shareholders are encouraged to review SEC filings and more information about McKesson, which are located on the company’s website. 
About McKesson
McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better.  We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting.  McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.  For more information, visithttp://www.mckesson.com.
Tables and full-text of earnings release also available for viewing and download in PDF format:McKesson Reports Fiscal 2013 Third-Quarter Results (PDF)

McKesson Declares Quarterly Dividend January 30, 2013

McKesson News Release:

McKesson Declares Quarterly Dividend January 30, 2013
January 30, 2013

SAN FRANCISCO--(BUSINESS WIRE)--January 30, 2013-- The Board of Directors of McKesson Corporation (NYSE:MCK) at its meeting today declared a regular dividend of twenty cents per share on Common Stock, payable on April 1, 2013, to stockholders of record on March 1, 2013.
McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visithttp://www.mckesson.com.

GlaxoSmithKline starts Phase III study to test combined BRAF/MEK inhibition in patients with BRAF positive melanoma following surgery

GSK News Release:


GlaxoSmithKline starts Phase III study to test combined BRAF/MEK inhibition in patients with BRAF positive melanoma following surgery

Issued: Friday 1st February 2013, London UK
GlaxoSmithKline plc. today announced the start of COMBI-AD, a  Phase III study evaluating the combination of dabrafenib, its BRAF inhibitor and trametinib, its MEK inhibitor as adjuvant therapy for melanoma.  This global study will investigate whether combining the two investigational agents can delay or prevent the recurrence of melanoma (Relapse Free Survival) in patients with Stage IIIa, IIIb, or IIIc BRAF V600E or V600K mutation-positive melanoma that has been completely removed by surgery.  The study will also evaluate the safety profile of the dabrafenib-trametinib combination in this treatment setting.
"The patients included in this trial are at high risk of their melanoma returning after surgery and there are currently few treatment options to reduce this risk" said Dr. Rafael Amado, Head of Oncology R&D for GlaxoSmithKline. "Given the efficacy and safety findings observed with combined dabrafenib-trametinib treatment in the metastatic setting, we are investigating whether the combination administered after surgery can help these patients live longer without melanoma recurrence.”
Two Phase III studies of combined dabrafenib-trametinib are ongoing in the metastatic BRAF V600 melanoma setting. (NCT01584648 and NCT01597908)
COMBI-AD: Study 115532 (NCT01682083) is a Phase III, randomised, double-blinded study comparing the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor, trametinib versus two placebos in the adjuvant treatment of melanoma after surgical resection. Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk [Stage IIIa (sentinel lymph node metastasis >1 mm), IIIb or IIIc] cutaneous melanoma will be screened for eligibility. Subjects will be randomised to receive either dabrafenib (150mg, twice daily) and trametinib (2mg, once daily) combination therapy or two placebos for 12 months.  The primary endpoint of the study is relapse-free survival.  The study seeks to enrol about 850 subjects from more than 200 investigative sites across the world.
About dabrafenibDabrafenib is an investigational, orally bioavailable inhibitor of the BRAF protein.  Dabrafenib was discovered and developed at GSK.  EU and US regulatory submissions for dabrafenib as a monotherapy treatment for BRAF V600 mutation-positive metastatic melanoma (150 mg once daily) were announced in August 2012.  Global submissions are ongoing.
About trametinibTrametinib is an investigational, orally bioavailable inhibitor of the MEK protein discovered by Japan Tobacco, Inc and in-licensed by GSK in 2006. Submission of a New Drug Application in the US for trametinib as a monotherapy treatment for BRAF V600 mutation-positive metastatic melanoma (2 mg once daily) was announced in August 2012. Submissions in the EU and other regions will follow in the coming months.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

Lilly Supports the Medical Community's Testimony on the Clinical Utility of Beta-Amyloid Imaging Agents, Such as Amyvi™ (Florbetapir F 18 Injection), During CMS Public Hearing (NYSE:LLY)

Lilly Supports the Medical Community's Testimony on the Clinical Utility of Beta-Amyloid Imaging Agents, Such as Amyvi™ (Florbetapir F 18 Injection), During CMS Public Hearing (NYSE:LLY)

AT&T 4G LTE Now Available in Ithaca

AT&T News Release:


AT&T 4G LTE Now Available in Ithaca

Customers to benefit from ultra-fast mobile Internet on the latest LTE devices

Ithaca, New York, January 31, 2013


AT&T* has turned on its 4G LTE network in Ithaca, bringing customers the latest generation of wireless network technology. The LTE upgrade to AT&T’s existing 4G network includes Ithaca, Cornell University, University Hill, College Town, West Hill, Buttermilk State Park, South Hill and East Ithaca.  In upstate New York, the 4G LTE network is also available in Albany, Syracuse, Rochester, Buffalo, Saratoga and Saratoga Springs.

AT&T’s innovation and investment has resulted in the largest 4G network in the nation, covering 288 million people with ultra-fast speeds and a more consistent user experience. That’s coverage in 3,000 more 4G cities and towns than Verizon.** Our 4G LTE network delivered faster average download speeds than any of our competitors in PCWorld’s most recent 13-market speed tests.

“The expansion of 4G LTE wireless network coverage is an incredible benefit for the residents of Ithaca,” said Ithaca Mayor Svante L. Myrick.  “This is great news for the economic development of Ithaca and for our citizens who depend on their wireless devices for conducting business, gathering information and staying connected with family and friends.”

Watch here to see several of the benefits AT&T 4G LTE provides, including:

Faster speeds. LTE technology is capable of delivering mobile Internet speeds up to 10 times faster than 3G***. Customers can stream, download, upload and game faster than ever before.
Cool new devices. AT&T offers several LTE-compatible devices, including new AT&T 4G LTE smartphones and tablets, such as the Sony Xperia™ TL, LG Optimus G™, Samsung Galaxy S III, Motorola ATRIX™ HD, HTC One™ X, Nokia Lumia 920, Samsung Galaxy Note™ II, HTC One™ X+, Samsung ATIV smart PC and ASUS VivoTab™ RT.
Faster response time. LTE technology offers lower latency, or the processing time it takes to move data through a network, such as how long it takes to start downloading a webpage or file once you’ve sent the request. Lower latency helps to improve services like mobile gaming, two-way video calling and telemedicine.
More efficient use of spectrum. Wireless spectrum is a finite resource, and LTE uses spectrum more efficiently than other technologies, creating more space to carry data traffic and services and to deliver a better network experience.
“We continue to see demand for mobile Internet skyrocket, and our 4G LTE network in Ithaca responds to what customers want from their mobile experience — more, faster, on the best devices,” said Marissa Shorenstein, president, AT&T New York.

AT&T’s 4G Network

AT&T’s 4G LTE network delivers speeds up to 10 times faster than 3G, as well as multiple innovations that optimize the network for performance. Our network’s radio components are placed close to the antenna at most cell sites, instead of inside the base station, which helps minimize power loss between the base station and antenna and, in turn, improves the performance of our 4G LTE network. The network also is designed with its core elements distributed across the country, which helps reduce latency, or the delay when using the Internet, because your request isn’t traveling as far.

Even as AT&T continues to expand its 4G LTE coverage, customers can get 4G speeds outside of 4G LTE areas on our 4G HSPA+ network, unlike competitors, where smartphone customers fall back to slower 3G technologies when outside of LTE coverage.

AT&T recently announced Project Velocity IP, its strategic plan to invest $14 billion over the next three years to expand its wireless and wireline IP broadband networks.  As part of Project Velocity IP,  AT&T’s 4G LTE network is expected expand to cover 300 million people by year-end 2014, and its wireline IP network is expected to extend to 57M customer locations, covering 75% of locations in AT&T’s wireline service area by year-end 2015.

*AT&T products and services are provided or offered by subsidiaries and affiliates of AT&T Inc. under the AT&T brand and not by AT&T Inc.

**4G speeds not available everywhere. Comparison based on U.S. cities and towns with 4G coverage.

***Limited 4G LTE availability in select markets. Deployment ongoing. 4G LTE device and data plan required. Up to 10x claim compares 4G LTE download speeds to industry average 3G download speeds. LTE is a trademark of ETSI. 4G speeds not available everywhere. Learn more about 4G LTE at att.com/network.

About AT&T

AT&T Inc. (NYSE:T) is a premier communications holding company and one of the most honored companies in the world. Its subsidiaries and affiliates – AT&T operating companies – are the providers of AT&T services in the United States and internationally. With a powerful array of network resources that includes the nation’s largest 4G network, AT&T is a leading provider of wireless, Wi-Fi, high speed Internet, voice and cloud-based services. A leader in mobile Internet, AT&T also offers the best wireless coverage worldwide of any U.S. carrier, offering the most wireless phones that work in the most countries. It also offers advanced TV services under the AT&T U-verse® and AT&T |DIRECTV brands. The company’s suite of IP-based business communications services is one of the most advanced in the world.

Additional information about AT&T Inc. and the products and services provided by AT&T subsidiaries and affiliates is available at http://www.att.com/aboutus or follow our news on @ATT, on Facebook at http://www.facebook.com/att and YouTube at http://www.youtube.com/att.

AT&T 4G LTE Available in Macon

AT&T News Release:


AT&T 4G LTE Available in Macon

Customers to benefit from ultra-fast mobile Internet on the latest LTE devices

Macon, Georgia, January 31, 2013


AT&T* has turned on its 4G LTE network in Macon, along I-75 and including Warner Robins, bringing customers the latest generation of wireless network technology. Watch here to see several of the benefits AT&T 4G LTE provides, including:

Faster speeds. LTE technology is capable of delivering mobile Internet speeds up to 10 times faster than 3G.** Customers can stream, download, upload and game faster than ever before.
Cool new devices. AT&T offers several LTE-compatible devices, including new AT&T 4G LTE smartphones and tablets, such as the Sony Xperia™ TL, LG Optimus G™, Samsung Galaxy S III, Motorola ATRIX™ HD, HTC One™ X, Nokia Lumia 920, Samsung Galaxy Note™ II, HTC One™ X+, Samsung ATIV smart PC and ASUS VivoTab™ RT.
Faster response time. LTE technology offers lower latency, or the processing time it takes to move data through a network, such as how long it takes to start downloading a webpage or file once you’ve sent the request. Lower latency helps to improve services like mobile gaming, two-way video calling and telemedicine.
More efficient use of spectrum. Wireless spectrum is a finite resource, and LTE uses spectrum more efficiently than other technologies, creating more space to carry data traffic and services and to deliver a better network experience.
“We continue to see demand for mobile Internet skyrocket, and our 4G LTE network in Macon responds to what customers want from their mobile experience — more, faster, on the best devices,” said Terry Smith, AT&T Director of External Affairs.

AT&T’s 4G Network

AT&T’s innovation and investment has resulted in the nation’s largest 4G network, covering 288 million people with ultra-fast speeds and a more consistent user experience. That’s coverage in 3,000 more 4G cities and towns than Verizon.*** Our 4G LTE network delivered faster average download speeds than any of our competitors in PCWorld’s most recent 13-market speed tests.

AT&T’s 4G LTE network delivers speeds up to 10 times faster than 3G, as well as multiple innovations that optimize the network for performance. Our network’s radio components are placed close to the antenna at most cell sites, instead of inside the base station, which helps minimize power loss between the base station and antenna and, in turn, improves the performance of our 4G LTE network. The network also is designed with its core elements distributed across the country, which helps reduce latency, or the delay when using the Internet, because your request isn’t traveling as far.

Even as AT&T continues to expand its 4G LTE coverage, customers can get 4G speeds outside of 4G LTE areas on our 4G HSPA+ network, unlike competitors, where smartphone customers fall back to slower 3G technologies when outside of LTE coverage.

AT&T’s focus to deliver the best possible mobile Internet experience goes beyond 4G to embrace additional connection technologies. AT&T operates the nation’s largest Wi-Fi network**** including more than 31,000 AT&T Wi-Fi Hot Spots at popular restaurants, hotels, bookstores and retailers across the country. Most AT&T smartphone customers get access to our entire national Wi-Fi network at no additional cost, and Wi-Fi usage doesn’t count against customers’ monthly wireless data plans.

AT&T also is a leading developer of Distributed Antenna Systems, which utilize multiple small antennas to maximize coverage and speed within stadiums, convention centers, office buildings, hotels and other areas where traditional coverage methods are challenging.

Over the past five years, AT&T invested more than $115 billion into operations and into acquiring spectrum and other assets that have enhanced our wireless and wired networks. Since 2007, AT&T has invested more capital into the U.S. economy than any other public company. In a July 2012 report, the Progressive Policy Institute ranked AT&T No. 1 on its list of U.S. “Investment Heroes.”

*AT&T products and services are provided or offered by subsidiaries and affiliates of AT&T Inc. under the AT&T brand and not by AT&T Inc.

**Limited 4G LTE availability in select markets. Deployment ongoing. 4G LTE device and data plan required. Up to 10x claim compares 4G LTE download speeds to industry average 3G download speeds. LTE is a trademark of ETSI. 4G speeds not available everywhere. Learn more about 4G LTE at att.com/network.

***4G speeds not available everywhere. Comparison based on U.S. cities and towns with 4G coverage.

****Access includes AT&T Wi-Fi Basic. A Wi-Fi enabled device required. Other restrictions apply. See www.attwifi.com for details and locations.

About AT&T

AT&T Inc. (NYSE:T) is a premier communications holding company and one of the most honored companies in the world. Its subsidiaries and affiliates – AT&T operating companies – are the providers of AT&T services in the United States and internationally. With a powerful array of network resources that includes the nation’s largest 4G network, AT&T is a leading provider of wireless, Wi-Fi, high speed Internet, voice and cloud-based services. A leader in mobile Internet, AT&T also offers the best wireless coverage worldwide of any U.S. carrier, offering the most wireless phones that work in the most countries. It also offers advanced TV services under the AT&T U-verse® and AT&T |DIRECTV brands. The company’s suite of IP-based business communications services is one of the most advanced in the world.

Additional information about AT&T Inc. and the products and services provided by AT&T subsidiaries and affiliates is available at http://www.att.com/aboutus or follow our news on @ATT, on Facebook at http://www.facebook.com/att and YouTube at http://www.youtube.com/att.

Amgen To Webcast 2013 Business Review Meeting On February 7

Amgen Press Release:


Amgen To Webcast 2013 Business Review Meeting On February 7

THOUSAND OAKS, Calif., Jan. 31, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will hold its Business Review Meeting on Thursday, Feb. 7, 2013, at the Mandarin Oriental Hotel, 80 Columbus Circle, New York City, beginning at 8 a.m. Eastern Standard Time. In the meeting, Robert A. Bradway, chairman and chief executive officer, Sean E. Harper, M.D., executive vice president, Research and Development, Anthony C. Hooper, executive vice president, Global Commercial Operations, and Jonathan M. Peacock, executive vice president and chief financial officer, will discuss the Company's plans to manage our diversified portfolio of in-market products, a strong emerging pipeline, and other initiatives that will drive future growth.

The webcast will be available to members of the news media, investors and the general public, and is expected to last approximately four hours.

The webcast of the meeting, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay at least 30 days after the event.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.